BioSpace News Archive

TTG Imaging Solutions, LLC announced executive leadership changes that will drive the company’s next phase of growth following its 9th acquisition in 2 years of Medical Imaging Technologies, an Akron, Ohio based nuclear medicine equipment and service organization.

Eli Lilly and Company (NYSE: LLY) will participate in Bernstein’s Second Annual Operational Decisions Conference on Thursday, Nov. 4 , 2021.

New subgroup analyses from the TULIP Phase III clinical trial program showed SAPHNELO, a first-in-class type I interferon antagonist, in addition to standard therapy, resulted in a greater reduction in systemic lupus erythematosus disease activity regardless of disease duration, standard therapy type and prior treatment, compared to standard therapy alone.

Mirum Pharmaceuticals, Inc. announced that new data will be presented at the American Association for the Study of Liver Disease annual congress, The Liver Meeting®, November 12-15, 2021.

Transplant Genomics, the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, is pleased to announce that over 500 patients have been enrolled in the TRULO observational study.

Arbutus Biopharma Corporation announced that the Company will be presenting data on the effects of its GalNAc-siRNA, AB-729, in chronic hepatitis B patients on nucleoside analogue therapy at The American Association for the Study of Liver Diseases – The Liver Meeting® 2021 – The Digital Experience™, taking place from November 12-15, 2021.

Brickell Biotech, Inc., a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, announced that it will report its financial results for the third quarter, ended September 30, 2021.

Paratek Pharmaceuticals, Inc. announced that the company will host a conference call and live audio webcast on Monday, Nov. 8, 2021 at 4:30 p.m.

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, provided a business update and reported financial results for the third quarter ended September 30, 2021.

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, announced that on October 29, 2021, the Company granted stock options to thirteen new employees of the Company.